Evidence map›Paper›PMID 39337261›Full record

ArticleInternational journal of molecular sciences2024

From In Vitro Promise to In Vivo Reality: An Instructive Account of Infection Model Evaluation of Antimicrobial Peptides.

Adam Carrera-Aubesart, Jiarui Li, Estefanía Contreras, Roberto Bello-Madruga, Marc Torrent, David Andreu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adam Carrera-AubesartDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0001-6196-1647
Jiarui LiDepartment of Biochemistry and Molecular Biology, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Estefanía ContrerasIntegrated Service for Laboratory Animals (SIAL), Faculty of Veterinary, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.ORCID 0000-0002-8645-2790
Roberto Bello-MadrugaDepartment of Biochemistry and Molecular Biology, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.ORCID 0009-0003-8474-3951
Marc TorrentDepartment of Biochemistry and Molecular Biology, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.ORCID 0000-0001-6567-3474
David AndreuDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-6317-6666

Funding

La Caixa Health Foundation HR17_00409Spanish Ministry of Science and Innovation María de Maeztu Program for Units of Excellence in R&D (CEX2018-000792-M)Spanish Ministry of Science and Innovation PDC2021-121544-I00/AEI/10.13039/501100011033Spanish Ministry of Science and Innovation PID2020-113184RB-C22/AEI/10.13039/501100011033Spanish Ministry of Science and Innovation PID2020-114627RB-I00/AEI/10.13039/501100011033
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are regarded as a promising alternative to traditional antibiotics in the face of ever-increasing resistance. However, many AMPs fail to progress into clinics due to unexpected difficulties found in preclinical in vivo phases. Our research has focused on crotalicidin (Ctn), an AMP from snake venom, and a fragment thereof, Ctn[15-34], with improved in vitro antimicrobial and anticancer activities and remarkable serum stability. As the retroenantio versions of both AMPs maintained favorable profiles, in this work, we evaluate the in vivo efficacy of both the native-sequence AMPs and their retroenantio counterparts in a murine infection model with

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesCrotalid VenomsDisease Models, AnimalFemaleHumansMiceMicrobial Sensitivity TestsPeptide FragmentsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidescrotalicidinCrotalid VenomsPeptide FragmentsAMPscrotalicidininfectionmurine modelretroenantiotopoisomers

Identifiers

PMID39337261
PMCPMC11431785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.